Dose adjustment of carboplatin in patients on hemodialysis

Guddati, Achuta; Joy, Parijat; Marak, Creticus
March 2014
Medical Oncology;Mar2014, Vol. 31 Issue 3, p1
Academic Journal
No abstract available.


Related Articles

  • Dosing carboplatin in patients assigned to hemodialysis. Mohs, Jocelyn // Hem/Onc Today;10/25/2009, Vol. 10 Issue 20, p7 

    The article focuses on the issue of determining the dose of the platinum-analog alkylating agent carboplatin for patients undergoing hemodialysis.

  • Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment. Heijns, Joan B.; van der Burg, Maria E. L.; van Gelder, Teun; Fieren, Marien W. J. A.; de Bruijn, Peter; van der Gaast, Ate; Loos, Walter J. // Cancer Chemotherapy & Pharmacology;Oct2008, Vol. 62 Issue 5, p841 

    Administration of chemotherapy in patients with renal failure, treated with hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) is still a challenge and literature data is scarce. Here we present a case study of a patient on CAPD, treated with weekly and three-weekly...

  • Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer. Hiraike, Mikako; Hiraki, Yoichi; Misumi, Nobuhiro; Hanada, Kiyonori; Tsuji, Yasuhiro; Kamimura, Hidetoshi; Karube, Yoshiharu; Kashiwabara, Kosuke // Cancer Chemotherapy & Pharmacology;Mar2012, Vol. 69 Issue 3, p845 

    Purpose: We examined a method to determine the dose of carboplatin and the timing of hemodialysis in carboplatin-based chemotherapy for a hemodialysis patient with cancer. Methods: Carboplatin-based chemotherapy was performed for a patient with small-cell lung cancer who was receiving...

  • Carboplatin. Wilkinson, Kathy // Clinical Journal of Oncology Nursing;May/Jun2001, Vol. 5 Issue 3, p125 

    Provides information on Carboplatin drug for cancer treatment. Indications for carboplatin; Effect on blood counts; Adverse reaction and effects. INSETS: Carboplatin (Paraplatin®) Patient Instruction Sheet;Calvert Formula for Carboplatin Dosing.

  • Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. Oguri, Tomoyo; Shimokata, Tomoya; Inada, Megumi; Ito, Isao; Ando, Yuichi; Sasaki, Yasutsuna; Hasegawa, Yoshinori // Cancer Chemotherapy & Pharmacology;Sep2010, Vol. 66 Issue 4, p813 

    To examine the safety of carboplatin-based chemotherapy and the applicability of the Calvert formula in patients with cancer who are undergoing hemodialysis. We treated two patients who were undergoing hemodialysis and received carboplatin-based chemotherapy to treat non-small-cell lung cancer...

  • Extension of the Calvert formula to patients with severe renal insufficiency. Oguri, Tomoyo; Shimokata, Tomoya; Ito, Isao; Yasuda, Yoshinari; Sassa, Naoto; Nishiyama, Masami; Hamada, Akinobu; Hasegawa, Yoshinori; Ando, Yuichi // Cancer Chemotherapy & Pharmacology;Jul2015, Vol. 76 Issue 1, p53 

    Purpose: The Calvert formula was derived from the study among patients with glomerular filtration rates (GFRs) of 33-135 ml/min, and it remains unclear whether the formula can be used to calculate optimal and safe dosages of carboplatin in patients with severe renal insufficiency. We evaluated...

  • Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. Veal, G. J.; Errington, J.; Tilby, M. J.; Pearson, A. D. J.; Foot, A. B. M.; McDowell, H.; Ellershaw, C.; Pizer, B.; Nowell, G. M.; Pearson, D. G.; Boddy, A. V. // British Journal of Cancer;3/12/2007, Vol. 96 Issue 5, p725 

    A pharmacokinetic–pharmacodynamic study was carried out to investigate the feasibility and potential importance of therapeutic monitoring following high-dose carboplatin treatment in children. High-dose carboplatin was administered over 3 or 5 days, with the initial dose based on renal...

  • Nephrotoxicity after high-dose carboplatin, etoposide and ifosfamide in germ-cell tumors: incidence and implications for hematologic recovery and clinical outcome. Beyer, J; Rick, O; Weinknecht, S; Kingreen, D; Lenz, K; Siegert, W // Bone Marrow Transplantation;11/15/97, Vol. 20 Issue 10, p813 

    High-dose carboplatin, etoposide and ifosfamide (CEI) is an active chemotherapy regimen (HDCT) in solid tumors and lymphomas. In patients with previous exposure to cisplatin, its nephrotoxicity is dose-limiting. To determine the implications of nephrotoxicity on hematological recovery and...

  • Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Veal, Gareth J.; English, Martin W.; Grundy, Richard G.; Shakespeare, Cay; Glaser, Adam; Waters, Fiona; Holden, Vicky; O'Meara, Anne; Michalski, Antony; Howe, Karen; Cole, Sue; Boddy, Alan V. // Cancer Chemotherapy & Pharmacology;Oct2004, Vol. 54 Issue 4, p295 

    An approach to carboplatin dosing in children with bilateral nephrectomy using a renal function-based dosing formula with a glomerular filtration rate of zero was investigated in the current study. Carboplatin exposure was determined in a total of nine courses of chemotherapy in four patients...

  • Prediction of carboplatin clearance from standard morphological and biological patient... Chatelut, Etienne; Canal, Pierre // JNCI: Journal of the National Cancer Institute;4/19/95, Vol. 87 Issue 8, p573 

    Determines a relationship between antineoplastic drug carboplatin clearance and patient characteristics. Factors influencing carboplatin's hematologic toxicity; Proposal for dosage adjustments based on isotopic determination; Dosage adjustments based on patient creatinine clearance.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics